Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropeginterferon in Cutaneous T-Cell Lymphoma
NCT07047885Phase 1Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2025
- Primary completion
- Jun 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of ropeginterferon alfa-2b in cutaneous T-cell lymphoma (CTCL) (4 arms), sponsored by Moffitt Cancer Center. Primary endpoints: Dose Limiting Toxicity at 6 weeks and Recommended Phase II Dose at 6 weeks. Started Aug 2025; status: recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT07047885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07047885.